Articles

Cost-effectiveness of ruxolitinib vs. Best Available Therapy in the treatment of myelofibrosis in Spain

Authors: Gómez-Casares MT, Hernández-Boluda JC, Jiménez-Velasco A, Martínez-López J, Ferrario MG, Gozalbo Irmina, Gostkorzewicz J, Subirá R

Journal: Journal of Health Economics & Outcomes Research (JHEOR)

Year: 2017

Reference: JHEOR 2017;5(2):162-74


Outside URL
Subscribe to Outcomes´10
Todos los campos marcados con un * son obligatorios
Responsible for the data: Outcomes'10, s.l.u., Purpose: Sending commercial communications. Legitimation: Art. 6.1 Consent of the interested party. Recipient: No data is transferred unless expressly authorised. You may exercise your rights on data protection (access, rectification, opposition, deletion, automated decisions, limitation of treatment, portability) by email at dpo@outcomes10.com. In any case, you can request the protection of the Spanish Data Protection Agency through its website www.aepd.es/. In addition, you can consult more information on the privacy policy
Logo
Aenor gestión de calidad
Aenor seguridad e información
Logotipo
Skip to content